Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment

Silke Polsfuss; Sabine Hofmann-Thiel; Matthias Merker; David Krieger; Stefan Niemann; Holger Rüssmann; Nicolas Schönfeld; Harald Hoffmann; Katharina Kranzer

doi:10.1093/cid/ciz074

Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment

Silke Polsfuss^*, Sabine Hofmann-Thiel, Matthias Merker, David Krieger, Stefan Niemann, Holger Rüssmann, Nicolas Schönfeld, Harald Hoffmann, Katharina Kranzer

^*Corresponding author for this work

Department of Internal Medicine III

62 Citations (Scopus)

Abstract

Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

Original language	English
Journal	Clinical Infectious Diseases
Volume	69
Issue number	7
Pages (from-to)	1229-1231
Number of pages	3
ISSN	1058-4838
DOIs	https://doi.org/10.1093/cid/ciz074
Publication status	Published - 13.09.2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1093/cid/ciz074

Cite this

@article{b9d7a86cfb5f43db9d2637db8e5539ce,

title = "Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment",

abstract = "Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.",

author = "Silke Polsfuss and Sabine Hofmann-Thiel and Matthias Merker and David Krieger and Stefan Niemann and Holger R{\"u}ssmann and Nicolas Sch{\"o}nfeld and Harald Hoffmann and Katharina Kranzer",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = sep,

day = "13",

doi = "10.1093/cid/ciz074",

language = "English",

volume = "69",

pages = "1229--1231",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment

AU - Polsfuss, Silke

AU - Hofmann-Thiel, Sabine

AU - Merker, Matthias

AU - Krieger, David

AU - Niemann, Stefan

AU - Rüssmann, Holger

AU - Schönfeld, Nicolas

AU - Hoffmann, Harald

AU - Kranzer, Katharina

N1 - Publisher Copyright: © 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/9/13

Y1 - 2019/9/13

N2 - Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

AB - Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

UR - https://www.scopus.com/pages/publications/85065770908

U2 - 10.1093/cid/ciz074

DO - 10.1093/cid/ciz074

M3 - Journal articles

C2 - 30933266

AN - SCOPUS:85065770908

SN - 1058-4838

VL - 69

SP - 1229

EP - 1231

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 7

ER -

Emergence of Low-level Delamanid and Bedaquiline Resistance during Extremely Drug-resistant Tuberculosis Treatment

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this